ARTERIAL GIPERTONIYA VA QANDLI DIABETNING BIRGALIKDA KECHISHIDA BUYRAK FAOLIYATI HOLATINI BAHOLASH

Authors

  • Soliyev Jaxongirxon Sobirxon o‘g‘li Kardiologiya yo‘nalishi klinik ordinatori, Central Asian Medical University

Keywords:

arterial gipertoniya, 2-tur qandli diabet, buyrak faoliyati, surunkali buyrak kasalligi, kreatinin, eGFR, albuminuriya, UACR, diabetik nefropatiya, arterial qon bosimi

Abstract

Arterial gipertoniya va qandli diabetning 2-turi yurak-qon tomir hamda buyrak kasalliklari rivojlanishi bilan chambarchas bog‘liq bo‘lgan surunkali patologik holatlardir. Ushbu kasalliklarning birgalikda kechishi buyrakning strukturaviy va funksional zararlanishi xavfini oshirib, surunkali buyrak kasalligining rivojlanishi va progressiyasiga olib kelishi mumkin. Mazkur tadqiqotning maqsadi arterial gipertoniya va 2-tur qandli diabet mavjud bemorlarda buyrak faoliyati holatini klinik va laborator ko‘rsatkichlar asosida baholashdan iborat. Tadqiqotda bemorlarning arterial qon bosimi, qandli diabet davomiyligi, kreatinin miqdori, hisoblangan glomerulyar filtratsiya tezligi (eGFR) hamda siydikdagi albumin/kreatinin nisbati (UACR) o‘rganildi. Kuzatuvlarda arterial qon bosimi nazoratining yetarli emasligi, qandli diabetning uzoq davom etishi, kreatinin miqdorining oshishi, eGFR pasayishi va albuminuriyaning kuchayishi buyrak faoliyatidagi o‘zgarishlar bilan bog‘liqligi aniqlandi. Natijalar arterial gipertoniya va qandli diabet birgalikda kechayotgan bemorlarda buyrak faoliyatini muntazam baholash, albuminuriyani erta aniqlash va arterial bosim hamda glyukemik nazoratni optimallashtirish muhimligini ko‘rsatadi.

References

American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl. 1):S246–S260.

American Diabetes Association Professional Practice Committee. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl.1).

American Diabetes Association. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl.1):S239–S251.

American Diabetes Association. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes Care. 2023.

de Boer I.H., Khunti K., Sadusky T., et al. Diabetes management in chronic kidney disease: a consensus report by the ADA and KDIGO. Diabetes Care. 2022;45(12):3075–3090.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(Suppl.4S):S117–S314.

Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International. 2022;102(5S):S1–S127.

Downloads

Published

2026-09-28